An approach aimed at the IL-33/ST2 path could be a potential therapeutic target for human patients suffering from chronic hepatitis and liver fibrosis (Hammerich and Tacke, 2014; Weiskirchen and Tacke, 2016; Zhang et al., 2016; Ma et al., 2020). This evidence concerns the gene IL33 and chronic hepatitis.